Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

UK Health Body Approves Novartis's Tasigna For CML

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/25/2012 | 01:16am CET

The U.K.'s health-cost regulator has decided to back an expensive cancer drug from Novartis AG (NVS) for treating chronic myeloid leukemia--but not one from U.S.-based Bristol-Myers Squibb Co. (BMY)--after the Swiss drug maker offered to cut the drug's price.

The independent National Institute for Clinical Excellence, known by its acronym NICE, said Wednesday it approved Novartis's Tasigna and the company's older drug, whose brand name is Glivec, for use in treating CML on the publicly funded National Health Service. The generic names for Tasigna and Glivec are nilotinib and imatinib, respectively.

However, NICE said it wasn't approving Bristol-Myers Squibb's Sprycel, also known as dasatinib.

CML is a cancer of blood-forming cells in the bone marrow that usually develops slowly, which is why it is described as a chronic form of the disease.

NICE director Carole Longson said: "The recommendations reaffirm the use of imatinib as an effective treatment for the majority of patients and a cost-effective use of NHS resources, and we are also very pleased to be able to add a further treatment option for these patients by recommending nilotinib.

"Although no trials directly comparing dasatinib and nilotinib were available, the committee concluded from indirect comparisons that dasatinib and nilotinib could be considered equally as effective in treating CML.

"However, the manufacturer of nilotinib has already agreed with the Department of Health to provide the drug to the NHS at a discounted price. This reduction in cost enabled the independent committee to approve nilotinib for use on the NHS."

Dasatinib and nilotinib both cost over GBP30,000 per patient a year and the standard dose of imatinib costs GBP20,000.

NICE didn't disclose the price discount offered by Novartis for nilotinib.

-By Sten Stovall, Dow Jones Newswires; +44 207 842 9292; sten.stovall@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVARTIS AG
01/19 NOVARTIS : Patent Issued for Solid Oral Formulations and Crystalline Forms of an..
01/19 NOVARTIS : Patent Issued for MELK Regulation for the Treatment of Breast Cancer ..
01/19 NOVARTIS : Patent Issued for Integrated OCT-Refractometer System for Ocular Biom..
01/19 Davos CEOs 'go local' on supply chain in Trump era
01/18 Drugmakers in Davos shift focus to chronic diseases of poor
01/16 NOVARTIS : invests in next generation therapies to reduce cardiovascular risk in..
01/13DJNOVARTIS : Supreme Court to Weigh How Soon Firms Can Sell Copycat Biotech Drugs
01/13 NOVARTIS : NICE approves kidney cancer drug for NHS use
01/12 NOVARTIS : "Combination Therapy Comprising an Inhibitor of Jak, Cdk, and Pim" in..
01/12 NOVARTIS : Patent Issued for Pharmaceutical Combination Comprising a Phosphatidy..
More news
Sector news : Pharmaceuticals - NEC
01/24DJMARKET SNAPSHOT : Dow Makes A Run At Elusive 20,000 Amid Earnings Fusillade
01/24 MORGAN STANLEY : Toronto biotech raises $200 million ahead of ADHD drug decision
01/24DJJOHNSON & JOHNSON : Revenue Rises But Forecast Disappoints
01/24 U.S. reaches settlement with Endo on pay-for-delay charges
01/20 European shares ease ahead of Trump inauguration
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
01/24 Notable earnings before Wednesday?s open
01/24 Intrexon to acquire GenVec in all-stock deal
01/24 We're Hesitant On AnaptysBio's IPO
01/20 The Most Important Keys To Celgene's Pipeline
01/20 FDA Baits Biosimilar Makers With Switching Guidance
Advertisement
Financials ($)
Sales 2016 48 737 M
EBIT 2016 11 773 M
Net income 2016 7 989 M
Debt 2016 15 018 M
Yield 2016 4,01%
P/E ratio 2016 20,51
P/E ratio 2017 19,81
EV / Sales 2016 4,08x
EV / Sales 2017 4,05x
Capitalization 183 809 M
More Financials
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 29
Average target price 79,1 $
Spread / Average Target 13%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Joseph Jimenez Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Kirsch Chief Financial Officer
Vasant Narasimhan Chief Medical Officer & Head-Drug Development
Srikant Madhav Datar Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG-4.32%183 809
JOHNSON & JOHNSON-1.13%309 896
ROCHE HOLDING LTD.0.39%200 025
PFIZER INC.-3.14%190 910
MERCK & CO., INC.4.99%170 419
SANOFI-1.66%103 847
More Results